Back to homepage

Haematology and Oncology

Advances in iron chelation therapy: transitioning to a new oral formulation

Authors: Nirmish R Shah

This review provides an overview of the currently available iron chelator formulations, with a focus on a comparison between deferasirox DT for oral suspension and deferasirox FCT. The new formulation may be associated with fewer side effects and has increased bioavailability. In addition, alternative strategies for iron chelation, such as combining two different iron chelators, will be discussed.

More

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

Authors: Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane, Irene Braña, Elisabet Sicart, Colin Miles, Michael M Lahn, Malcolm I Mitchell, Jordi Rodon

In this relative bioavailability study comparing galunisertib formulations after a single dose, RCD and RCS formulations had similar exposure and safety profile compared with the HSWG formulation.

More

Evaluating cost benefits of combination therapies for advanced melanoma

Authors: Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, Wes Yin

The model presented in this study was used to analyze the clinical and economic benefit of using combination therapies in advanced melanoma patients with the BRAF V600 mutation. The analysis suggests dabrafenib + trametinib therapy is associated with less patient time and lower costs relative to nivolumab + ipilimumab to gain similar progression-free survival and overall response rate benefits.

More

Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data

Authors: Paul Harper, Emmanuel J Favaloro, Julie Curtin, Chris Barnes, Scott Dunkley

Human plasma-derived factor VIII/von Willebrand factor complex concentrates are used to control bleeding in patients with von Willebrand disease (VWD) or haemophilia A (HA). This article provides an extensive overview of the molecular properties, in addition to pharmacokinetic, efficacy and safety data, and case studies of clinical experience of one such concentrate, Biostate.

More

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies

Authors: Sarah L Scarpace

Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. This paper provides an overview of drug therapy options for squamous cell NSCLC with a focus on the evidence and clinical application of the anti-PD1 therapies. A comparison of the dosing, administration, indications, and differences in the measurement of PD-L1 expression in the clinical trials of nivolumab and pembrolizumab is also provided.

More